Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
... studies conducted to assess NT-201 in upper
limb post-stroke spasticity, pre-treated cervical ... type A free from complexing proteins) in upper
limb spasticity patients.
Eric Pappert, M.D., ... free from complexing proteins) in upper
limb post-stroke spasticity patients authored by P. ...
Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
... placebo-controlled spasticity trial and one upper
limb spasticity trial -- were presented at the ... addition, NT-201 showed results in treating upper
limb spasticity sufferers of various etiologies ... (blepharospasm, cervical dystonia, and upper
limb spasticity) have been included (n=539 NT 201, ...
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
... SB-509 (30 mg of SB-509 per leg) into the lower
limb every 2
months. The remaining group ... SB-509 (30 mg of SB-509 per leg) into the lower
limb and will be treated
every 3 months. The remaining ... SB-509 (30 mg of SB-509 per leg) into the lower
limb every 2
months. The remaining group ...
Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
... Mason University,
researchers measured the upper
limb volume of 196 newly diagnosed breast
cancer ... subclinical lymphedema, as defined by a
change in
limb volume of >75cc; and all subjects showed a ... and water displacement to track
changes in
limb circumference and size as well as on patients to ...
Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
... amputations in patients suffering from
critical
limb ischemia. Sanofi-aventis previously reported ... the desired treatment profile for
critical
limb ischemia, and perhaps for earlier stages of ... trial
in approximately 500 patients with critical
limb ischemia. Four doses of 4
mg each will be ...
VA Studies Advanced Prosthetic Arm
... study of an advanced artificial arm that easily allows those with severe
limb loss to pick up a key or hold a pencil.
"This arm is a high-tech ... first large-scale testing of the arm, which allows those who have lost a
limb up to their shoulder joint to perform movements while reaching over their ...
Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
... efficacy and safety data in patients with focal dystonia and upper
limb spasticity will be presented at the American Academy of Neurology's (AAN) ... analyses, 6 clinical trials (blepharospasm, cervical dystonia and upper
limb spasticity) were included (n=539 NT-201, n=442 BoNT and n=75 placebo ...
ThermoGenesis Announces MXP Involvement in New Regenerative Medicine Initiatives
... effect of bone marrow derived mononuclear cells on patients with critical
limb ischemia (CLI). In addition, ThermoGenesis announced the launch of its ... stem cells to prevent amputation by restoring blood flow to the affected
limb is being studied in a number of clinical settings.
"We are pleased ...
Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
... injection of 60 mg
of SB-509 (30 mg of SB-509 per leg) into the lower
limb and will be treated
every 3 months. The remaining group (approximately 15 ... injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into
the lower
limb every 2 months. The remaining group (approximately 15
subjects) will ...
Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
... blood sugar(3), putting them at serious risk for debilitating or potentially fatal complications including heart disease, stroke, nerve damage, lower
limb amputation, vision loss and kidney disease(4).
About Lilly
Lilly, a leading innovation-driven corporation, is developing a growing ...
Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
... mild to moderate and may include bone pain, hot flashes, back pain, nausea, joint pain, shortness of breath, tiredness, coughing, constipation,
limb pain, chest pain and headache.
Gleevec important safety information
Fetal harm can occur when administered to a pregnant woman; therefore, ...
Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
... or heart attack) occurring during related hospitalization, target vessel revascularization (TVR) through nine months and amputation of the treated
limb through nine months.
The EPIC Stent is a next-generation product that builds on Boston Scientific's long-time leadership in the peripheral ...
Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
... sites throughout the United States and Europe. The study will evaluate one-year patency in patients with leg pain (claudication) and one-year
limb salvage in patients with critical leg ischemia (CLI) and include third party review of results by independent core-labs.
"As one of the most ...
ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
... Commenting on the work, DFCon organizer and one of the study's co-authors, Dr. David Armstrong, Professor of Surgery and Director, Southern Arizona
limb Salvage Alliance (SALSA) University of Arizona College of Medicine stated, "We have been provisionally impressed with this modality. We believe ...
Lake Hospital System Receives $60,000 Grant for Groundbreaking Music Therapy Study
... pressure and blood lipids have decreased occurrence of serious complications, including cardiovascular disease, kidney damage, blindness and lower
limb amputations," explained Martin L. Mandel, M.D., F.A.C.E., a Lake Hospital System endocrinologist who is serving as the study's medical advisor. "It ...
Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
... mild to moderate and may include bone pain, hot flashes, back pain, nausea, joint pain, shortness of breath, tiredness, coughing, constipation,
limb pain, chest pain and headache.
Disclaimer
The foregoing release contains forward-looking statements that can be identified by ...
Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
... 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness (excluding vertigo) (each 17%), pain in
limb and abdominal pain (each 15%), bone pain (14%), back pain and hypotension (each 13%), herpes zoster, nasopharyngitis, upper respiratory tract ...
Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
... 22%), dyspnea (21%), cough and
insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness
(excluding vertigo) (each 17%), pain in
limb and abdominal pain (each 15%),
bone pain (14%), back pain and hypotension (each 13%), herpes zoster,
nasopharyngitis, upper respiratory tract ...
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
... 22%), dyspnea (21%), cough and
insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness
(excluding vertigo) (each 17%), pain in
limb and abdominal pain (each 15%),
bone pain (14%), back pain and hypotension (each 13%), herpes zoster,
nasopharyngitis, upper respiratory tract ...
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
... mild to moderate and may include bone pain, hot flashes, back pain, nausea, joint pain, shortness of breath, tiredness, coughing, constipation,
limb pain, chest pain and headache.
About Zometa
Zometa(R) (zoledronic acid) is indicated for patients with multiple myeloma and documented ...
Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
... bitter taste. Also commonly reported were anesthetic
complications, indicative of the restoration of neuromuscular function,
including movement of a
limb or the body or coughing during the anesthetic
procedure or during surgery, grimacing, or suckling on the endotracheal
tube. In a few individuals, ...
Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
... along the spine on both sides of the body. A second cohort of
5 subjects will receive 60 mg of SB-509 in a divided dose into the muscles
in the lower
limb in both legs. Each subject will receive a total of two
treatments of 60 mg of SB-509 intramuscularly three months apart on Day 0
and Day 90. The ...
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
... 22%),
dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%),
neutropenia and dizziness (excluding vertigo) (each 17%), pain in
limb and
abdominal pain (each 15%), bone pain (14%), back pain and hypotension (each
13%), herpes zoster, nasopharyngitis, upper respiratory tract ...
BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
... bitter taste. Also commonly reported were anesthetic
complications, indicative of the restoration of neuromuscular function,
including movement of a
limb or the body or coughing during the anesthetic
procedure or during surgery, grimacing, or suckling on the endotracheal
tube. In a few individuals, ...
Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
... mild to moderate and may include bone pain, hot flashes, back
pain, nausea, joint pain, shortness of breath, tiredness, coughing,
constipation,
limb pain, chest pain and headache.
Disclaimer
The foregoing release contains forward-looking statements that can be
identified by terminology such as ...
Cardium and Tissue Repair Company's Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
... LAC-USC Medical Center (Los Angeles, CA); Dr. Roy Kroeker
DPM (Fresno, CA); Johns Hopkins Medical Center (Baltimore, MD), North
American Center for
limb Preservation (New Haven, CT); Doctor's Research
Network (Miami, FL); University of Miami (Miami, FL); Bay Pines VAHCS (Bay
Pines, FL); Village ...
MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
... foot infection. Infected foot ulcers can result in bone
infection (osteomyelitis) or progressive gangrene, and are the major
immediate cause of lower
limb amputation. Diabetes is now the top cause of
non-traumatic leg amputations in the developed world. Furthermore, foot
ulcers are now the most frequent ...
VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
... mild to moderate and may include bone pain, hot flashes, back
pain, nausea, joint pain, shortness of breath, tiredness, coughing,
constipation,
limb pain, chest pain and headache.
Disclaimer
The foregoing release contains forward-looking statements that can be
identified by terminology such as ...
Aung FootHealth Clinics & Advanced Wound Care Center Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Trial
... and Aung FootHealth Clinics
& Advanced Wound Care Center has been a leader in the field of Podiatric
Medicine specializing in Advanced Wound Care,
limb Preservation and
Amputation Prevention. Most chronic/long standing wounds that are treated
in our wound care center heal within 8-12 weeks. In fact, ...
Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
... transport agents, announced today that it has
started testing its lead product, Hemospan(R), in a Phase II clinical study
involving chronic critical
limb ischemia (CCLI) patients.
The single-blind, placebo-controlled study at the Karolinska Institute
in Stockholm, Sweden is designed to evaluate the ...
Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
... two groups in a 2:1 ratio. The larger group is
being treated by intramuscular injection of 60 mg of SB-509 (30 mg of
SB-509 per leg) into the lower
limb every 2 months. The remaining group is
receiving an equal volume of placebo on the same schedule. Each subject
will receive a total of three ...
Cardiologists Tackle 'Next Frontier' in Cardiovascular Disease
... with a catheter.
"Without these advanced procedures, many of these patients would
continue to get more and more sick, and some would face
limb amputation and
other life-threatening complications of the disease," said Dr. Kenneth
Saland, an interventional cardiologist at Presbyterian Hospital ...
Edwards' Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
... from lower-extremity PAD, which
affects mostly men and women older than 50 years. Without an effective
treatment, PAD can develop into critical
limb ischemia, a severe
obstruction of the arteries with decreased blood flow to the lower
extremities that may result in amputation. Edwards is ...
Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
... meningococcal disease will die. Of those who survive, up to
one in five suffer permanent disabilities such as hearing loss,
neurological damage and
limb amputations. Meningococcal disease often
begins with symptoms that can be mistaken for common viral illnesses, such
as the flu. But unlike more ...
MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
... foot infection. Infected foot
ulcers can result in bone infection (osteomyelitis) or progressive
gangrene, and are the major immediate cause of lower
limb amputation.
Diabetes is now the top cause of non-traumatic leg amputations in the
developed world. Furthermore, foot ulcers are now the most frequent ...
TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
... diabetic foot infection patients in a
double-blind phase 2 trial. The company has first-in-class phase 1-ready
drug candidates for treating critical
limb ischemia and
retinopathy/age-related macular degeneracy, and advanced preclinical
candidates for chronic Hepatitis C virus infection and cancer. ...
Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh
to be Presented at European Vascular Symposium
... or grafted blood vessel and lead to
limb amputation.
- When comparing the ... overall incidence of amputation and prolonged
limb retention time.
The control group had ... higher probability of losing
their
limb compared to the treatment arm.
- The ...
Sangamo BioSciences Announces Presentation of Phase 1 ZFP
Therapeutic Data at American Diabetes Association Meeting
... evaluation of pain and clinical effects
on lower
limb diabetic neuropathy at one, two, three and six ... SB-509 (30 mg of SB-509 per
leg) into the lower
limb every 2 months. The remaining ... SB-509 (30 mg of SB-509 per
leg) into the lower
limb every 3 months. The remaining ...
Beike Biotechnology Study Suggests Adult Stem Cells Show Promise
for Peripheral Vascular Disease
... comparing
the relative improvement of lower
limb ischemia (lack of blood
supply) between ...
At 12 weeks, primary symptoms, including lower
limb pain and
coldness, were significantly improved in 137 (90.1%) of the
patients;
limb ulcers improved or healed in 46 (86.8%) of the ...